http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 06 Oct 2026 05:16:47 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Raymond+James+Reiterates+Strong+Buy+Rating+on+Tyra+Biosciences+%28TYRA%29/27151045.html <p>Raymond James analyst Chris Raymond reiterated a Strong Buy rating and $50.00 price target on Tyra Biosciences (NASDAQ: TYRA).</p><p>The analyst comments "Remain Strong Buy rated on TYRA shares after hosting CEO Todd Harris for a fireside chat as part of our BioPharma CEO Strategy Series (contact your RJ rep for a replay of the call). Most of the conversation revolved around the opportunity for lead asset dabogratinib (dabo) in non-muscle invasive bladder cancer (NMIBC), where TYRA recently reported initial P2 data. Although dabo fell shy of the 70% 3-month CR rate that TYRA originally had estimated as the bar for http://www.streetinsider.com/Analyst+Comments/Raymond+James+Reiterates+Strong+Buy+Rating+on+Tyra+Biosciences+%28TYRA%29/27151045.html Tue, 06 Oct 2026 05:16:47 -0400 TYRA http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html <p>William Blair Adjusts October Analyst Conviction List Names.</p><p>The analyst comments "The William Blair Analyst Conviction List is a bottom-up list published monthly. It has been compiled by requesting each analyst to select up to two of their highest-conviction stocks over the next six months. The objective is to identify nearer-term ideas where analysts have a high degree of conviction of strong performance. Our list is provided on page 2, sorted by market cap within sectors. Following the list, we provide a short rationale for any stock that has been added or removed for the coming month, links to any notes http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html Thu, 01 Oct 2026 07:11:01 -0400 CASY CHYM CRDO DAVE DNTH RELY TWLO TYRA http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html <p>William Blair Adjusts October Analyst Conviction List Names.</p><p>The analyst comments "The William Blair Analyst Conviction List is a bottom-up list published monthly. It has been compiled by requesting each analyst to select up to two of their highest-conviction stocks over the next six months. The objective is to identify nearer-term ideas where analysts have a high degree of conviction of strong performance. Our list is provided on page 2, sorted by market cap within sectors. Following the list, we provide a short rationale for any stock that has been added or removed for the coming month, links to any notes http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html Thu, 01 Oct 2026 07:11:01 -0400 CASY CHYM CRDO DAVE DNTH RELY TWLO TYRA http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html <p>William Blair Adjusts October Analyst Conviction List Names.</p><p>The analyst comments "The William Blair Analyst Conviction List is a bottom-up list published monthly. It has been compiled by requesting each analyst to select up to two of their highest-conviction stocks over the next six months. The objective is to identify nearer-term ideas where analysts have a high degree of conviction of strong performance. Our list is provided on page 2, sorted by market cap within sectors. Following the list, we provide a short rationale for any stock that has been added or removed for the coming month, links to any notes http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html Thu, 01 Oct 2026 07:11:01 -0400 CASY CHYM CRDO DAVE DNTH RELY TWLO TYRA http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html <p>William Blair Adjusts October Analyst Conviction List Names.</p><p>The analyst comments "The William Blair Analyst Conviction List is a bottom-up list published monthly. It has been compiled by requesting each analyst to select up to two of their highest-conviction stocks over the next six months. The objective is to identify nearer-term ideas where analysts have a high degree of conviction of strong performance. Our list is provided on page 2, sorted by market cap within sectors. Following the list, we provide a short rationale for any stock that has been added or removed for the coming month, links to any notes http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html Thu, 01 Oct 2026 07:11:01 -0400 CASY CHYM CRDO DAVE DNTH RELY TWLO TYRA http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html <p>William Blair Adjusts October Analyst Conviction List Names.</p><p>The analyst comments "The William Blair Analyst Conviction List is a bottom-up list published monthly. It has been compiled by requesting each analyst to select up to two of their highest-conviction stocks over the next six months. The objective is to identify nearer-term ideas where analysts have a high degree of conviction of strong performance. Our list is provided on page 2, sorted by market cap within sectors. Following the list, we provide a short rationale for any stock that has been added or removed for the coming month, links to any notes http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html Thu, 01 Oct 2026 07:11:01 -0400 CASY CHYM CRDO DAVE DNTH RELY TWLO TYRA http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html <p>William Blair Adjusts October Analyst Conviction List Names.</p><p>The analyst comments "The William Blair Analyst Conviction List is a bottom-up list published monthly. It has been compiled by requesting each analyst to select up to two of their highest-conviction stocks over the next six months. The objective is to identify nearer-term ideas where analysts have a high degree of conviction of strong performance. Our list is provided on page 2, sorted by market cap within sectors. Following the list, we provide a short rationale for any stock that has been added or removed for the coming month, links to any notes http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html Thu, 01 Oct 2026 07:11:01 -0400 CASY CHYM CRDO DAVE DNTH RELY TWLO TYRA http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html <p>William Blair Adjusts October Analyst Conviction List Names.</p><p>The analyst comments "The William Blair Analyst Conviction List is a bottom-up list published monthly. It has been compiled by requesting each analyst to select up to two of their highest-conviction stocks over the next six months. The objective is to identify nearer-term ideas where analysts have a high degree of conviction of strong performance. Our list is provided on page 2, sorted by market cap within sectors. Following the list, we provide a short rationale for any stock that has been added or removed for the coming month, links to any notes http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html Thu, 01 Oct 2026 07:11:01 -0400 CASY CHYM CRDO DAVE DNTH RELY TWLO TYRA http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html <p>William Blair Adjusts October Analyst Conviction List Names.</p><p>The analyst comments "The William Blair Analyst Conviction List is a bottom-up list published monthly. It has been compiled by requesting each analyst to select up to two of their highest-conviction stocks over the next six months. The objective is to identify nearer-term ideas where analysts have a high degree of conviction of strong performance. Our list is provided on page 2, sorted by market cap within sectors. Following the list, we provide a short rationale for any stock that has been added or removed for the coming month, links to any notes http://www.streetinsider.com/Analyst+Comments/William+Blair+Adjusts+October+Analyst+Conviction+List+Names/27131479.html Thu, 01 Oct 2026 07:11:01 -0400 CASY CHYM CRDO DAVE DNTH RELY TWLO TYRA http://www.streetinsider.com/Analyst+Comments/Raymond+James+Adjusts+Analyst+Current+Favorites+List/27093048.html <p>Raymond James Adjusts Analyst Current Favorites List</p><ul><li><strong>ADDS</strong>: Climb Bio (NASDAQ: CLYM)</li><li><strong>REMOVES</strong>: Tyra Biosciences (NASDAQ: TYRA)</li></ul><p>The analyst comments "Climb Bio, Inc. (CLYM) is our Analyst Current Favorite given what we think is an increasingly derisked setup for both of CLYM’s lead assets – CLYM116 and budoprutug. For anti-APRIL antibody CLYM116, recent Phase 1 data demonstrated the ability to achieve strong levels of IgA reduction with a plausible every 3-month dosing scheme, which could lead to a best-in-class profile in this expanding multi-billion dollar market. CLYM anticipates sharing initial data from a Phase 2 study next year, which should solidify CLYM116’s efficacy http://www.streetinsider.com/Analyst+Comments/Raymond+James+Adjusts+Analyst+Current+Favorites+List/27093048.html Wed, 23 Sep 2026 06:31:22 -0400 CLYM TYRA http://www.streetinsider.com/Analyst+Comments/Raymond+James+Adjusts+Analyst+Current+Favorites+List/27093048.html <p>Raymond James Adjusts Analyst Current Favorites List</p><ul><li><strong>ADDS</strong>: Climb Bio (NASDAQ: CLYM)</li><li><strong>REMOVES</strong>: Tyra Biosciences (NASDAQ: TYRA)</li></ul><p>The analyst comments "Climb Bio, Inc. (CLYM) is our Analyst Current Favorite given what we think is an increasingly derisked setup for both of CLYM’s lead assets – CLYM116 and budoprutug. For anti-APRIL antibody CLYM116, recent Phase 1 data demonstrated the ability to achieve strong levels of IgA reduction with a plausible every 3-month dosing scheme, which could lead to a best-in-class profile in this expanding multi-billion dollar market. CLYM anticipates sharing initial data from a Phase 2 study next year, which should solidify CLYM116’s efficacy http://www.streetinsider.com/Analyst+Comments/Raymond+James+Adjusts+Analyst+Current+Favorites+List/27093048.html Wed, 23 Sep 2026 06:31:22 -0400 CLYM TYRA http://www.streetinsider.com/Analyst+PT+Change/Tyra+Biosciences+%28TYRA%29+PT+Lowered+to+%2440+at+Oppenheimer/27087762.html Oppenheimer analyst Mazahir Alimohamed lowered the price target on Tyra Biosciences (NASDAQ: TYRA) to $40.00 (from $50.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Tyra+Biosciences+%28TYRA%29+PT+Lowered+to+%2440+at+Oppenheimer/27087762.html Tue, 22 Sep 2026 08:00:20 -0400 TYRA http://www.streetinsider.com/Analyst+PT+Change/Tyra+Biosciences+%28TYRA%29+PT+Lowered+to+%2429+at+H.C.+Wainwright/27087611.html (Updated - September 22, 2026 7:37 AM EDT) <p>H.C. Wainwright analyst Mitchell Kapoor lowered the price target on Tyra Biosciences (NASDAQ: TYRA) to $29.00 (from $30.00) while maintaining a Buy rating.</p><p>The analyst commented: "Lavengratinib’s +2.4cm/year low-dose AHV supports oral FGFR inhibition in ACH. Abbisko Therapeutics (2256.HK; not rated) reported preliminary Phase 2 ABSK061-202 data in seven children ages 6-12 receiving lavengratinib 0.064mg/kg QD, with mean annualized height velocity (AHV) improving +2.4cm/year from baseline at Week 27 and 100% (7/7) meeting the ≥25% improvement responder definition. No serious AEs, AE-related discontinuations, hyperphosphatemia, or corneal toxicity were reported, and Abbisko said the first http://www.streetinsider.com/Analyst+PT+Change/Tyra+Biosciences+%28TYRA%29+PT+Lowered+to+%2429+at+H.C.+Wainwright/27087611.html Tue, 22 Sep 2026 07:37:41 -0400 TYRA http://www.streetinsider.com/Analyst+Comments/Tyra+Biosciences+%28TYRA%29+PT+Lowered+to+%2429+at+H.C.+Wainwright/27087611.html (Updated - September 22, 2026 7:37 AM EDT) <p>H.C. Wainwright analyst Mitchell Kapoor lowered the price target on Tyra Biosciences (NASDAQ: TYRA) to $29.00 (from $30.00) while maintaining a Buy rating.</p><p>The analyst commented: "Lavengratinib’s +2.4cm/year low-dose AHV supports oral FGFR inhibition in ACH. Abbisko Therapeutics (2256.HK; not rated) reported preliminary Phase 2 ABSK061-202 data in seven children ages 6-12 receiving lavengratinib 0.064mg/kg QD, with mean annualized height velocity (AHV) improving +2.4cm/year from baseline at Week 27 and 100% (7/7) meeting the ≥25% improvement responder definition. No serious AEs, AE-related discontinuations, hyperphosphatemia, or corneal toxicity were reported, and Abbisko said the first http://www.streetinsider.com/Analyst+Comments/Tyra+Biosciences+%28TYRA%29+PT+Lowered+to+%2429+at+H.C.+Wainwright/27087611.html Tue, 22 Sep 2026 07:37:41 -0400 TYRA http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Tyra+Biosciences%2C+Inc.+++++++++++++++++Filed+by%3A+BIOTECHNOLOGY+VALUE+FUND+L+P/27086088.html si-local-file:///var/storage/secattach/20260921/27086088.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Tyra+Biosciences%2C+Inc.+++++++++++++++++Filed+by%3A+BIOTECHNOLOGY+VALUE+FUND+L+P/27086088.html Mon, 21 Sep 2026 17:21:00 -0400 TYRA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tyra+Biosciences%2C+Inc.++++For%3A+Sep+15++Filed+by%3A+Harris+Todd/27077144.html si-local-file:///var/storage/secattach/20260917/27077144.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tyra+Biosciences%2C+Inc.++++For%3A+Sep+15++Filed+by%3A+Harris+Todd/27077144.html Thu, 17 Sep 2026 19:29:00 -0400 TYRA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tyra+Biosciences%2C+Inc.++++For%3A+Sep+15++Filed+by%3A+Rueb+Yuliya/27077142.html si-local-file:///var/storage/secattach/20260917/27077142.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tyra+Biosciences%2C+Inc.++++For%3A+Sep+15++Filed+by%3A+Rueb+Yuliya/27077142.html Thu, 17 Sep 2026 19:26:00 -0400 TYRA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tyra+Biosciences%2C+Inc.++++For%3A+Sep+15++Filed+by%3A+Fuhrman+Alan/27077140.html si-local-file:///var/storage/secattach/20260917/27077140.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tyra+Biosciences%2C+Inc.++++For%3A+Sep+15++Filed+by%3A+Fuhrman+Alan/27077140.html Thu, 17 Sep 2026 19:25:00 -0400 TYRA http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Tyra+Biosciences%2C+Inc.+++++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./27076334.html si-local-file:///var/storage/secattach/20260917/27076334.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Tyra+Biosciences%2C+Inc.+++++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./27076334.html Thu, 17 Sep 2026 16:32:00 -0400 TYRA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tyra+Biosciences%2C+Inc.++++For%3A+Sep+15++Filed+by%3A+Shah+Rajeev+M./27076326.html si-local-file:///var/storage/secattach/20260917/27076326.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Tyra+Biosciences%2C+Inc.++++For%3A+Sep+15++Filed+by%3A+Shah+Rajeev+M./27076326.html Thu, 17 Sep 2026 16:32:00 -0400 TYRA http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Tyra+Biosciences%2C+Inc.+++++++++++++++++Filed+by%3A+Paradigm+Biocapital+Advisors+LP/27075873.html si-local-file:///var/storage/secattach/20260917/27075873.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Tyra+Biosciences%2C+Inc.+++++++++++++++++Filed+by%3A+Paradigm+Biocapital+Advisors+LP/27075873.html Thu, 17 Sep 2026 16:06:00 -0400 TYRA http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Tyra+Biosciences%2C+Inc.+++++++++++++++/27060585.html si-local-file:///var/storage/secattach/20260915/27060585.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Tyra+Biosciences%2C+Inc.+++++++++++++++/27060585.html Tue, 15 Sep 2026 06:05:00 -0400 TYRA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tyra+Biosciences%2C+Inc.++++For%3A+Sep+14/27060579.html si-local-file:///var/storage/secattach/20260915/27060579.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Tyra+Biosciences%2C+Inc.++++For%3A+Sep+14/27060579.html Tue, 15 Sep 2026 06:05:00 -0400 TYRA http://www.streetinsider.com/Analyst+Comments/Cantor+Fitzgerald+Reiterates+Overweight+Rating+on+Tyra+Biosciences+%28TYRA%29/27056594.html <p>Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating and on Tyra Biosciences (NASDAQ: TYRA).</p><p>The analyst commented, "On Friday (9/11), we hosted CEO Todd Harris, CFO Alan Fuhrman and CMO Doug Warner for an investor breakfast following the company’s Phase 2 SURF302 data in FGFR3+ IR-NMIBC (intermediate-risk non-muscle-invasive bladder cancer). We believe there is a meaningful disconnect between dabo’s blockbuster potential and the stock’s reaction, particularly following what we view as a major de-risking event. In our view, investors may be misunderstanding the unmet need in IR-NMIBC and, importantly, applying an ablative efficacy framework to Phase 2 data that we http://www.streetinsider.com/Analyst+Comments/Cantor+Fitzgerald+Reiterates+Overweight+Rating+on+Tyra+Biosciences+%28TYRA%29/27056594.html Mon, 14 Sep 2026 09:53:03 -0400 TYRA http://www.streetinsider.com/Equity+Offerings/Tyra+Biosciences+prices+%24400+million+stock+offering+at+%2422.03/27055079.html <p>Tyra Biosciences, Inc. (Nasdaq: TYRA) has priced an underwritten public offering of common stock and pre-funded warrants expected to raise approximately $400 million in gross proceeds, according to a company statement.</p> <p>The Carlsbad, California-based clinical-stage biotechnology company is selling 9,079,000 shares of common stock at $22.03 per share. In addition, pre-funded warrants to purchase 9,078,529 shares of common stock are being offered at $22.029 per share, reflecting the share price minus the $0.001 exercise price per warrant. The offering is expected to close on September 15, 2026, subject to customary closing conditions.</p> <p>Tyra said it intends to use the net proceeds to http://www.streetinsider.com/Equity+Offerings/Tyra+Biosciences+prices+%24400+million+stock+offering+at+%2422.03/27055079.html Mon, 14 Sep 2026 06:45:23 -0400 TYRA